-
Endo Pharmaceuticals Inc. et al v. Teva Pharmaceuticals USA Inc. et al DC CAFC
- 1:14-cv-01389
- D. Del.
- Judge: Richard G. Andrews
- Filed: 11/07/2014
- Closed: 05/20/2019
- Latest Docket Entry: 10/16/2020
- PACER
- Docket updated daily
2
Plaintiffs
3
Defendants
1
Accused
Product
2
Patents-in-Suit
1,656
Days in
Litigation
-
Endo Pharmaceuticals Inc. et al v. Teva Pharmaceuticals USA Inc. et al DC CAFC
- 1:14-cv-01389
- D. Del.
- Judge: Richard G. Andrews
- Filed: 11/07/2014
- Closed: 05/20/2019
- Latest Docket Entry: 10/16/2020
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A hydrochloride salt of oxymorphone comprising less than 0.001% of 14-hydroxymorphinone.
|
Valid
Entry 218 Entry 203 |
2 |
The hydrochloride salt of claim 1 comprising less than 0.0005% of 14-hydroxymorphinone.
|
Valid
Entry 218 Entry 203 |
3 |
A pharmaceutical acceptable form comprising the oxymorphone hydrochloride according to claim 1.
|
Valid
Entry 218 Entry 203 |
4 |
A hydrochloride salt of a morphinan-6-one compound corresponding to Formula (2): <chemistry id="CHEM-US-00026" num="00026"><img id="EMI-C00026" he="38.52mm" wi="54.10mm" file="US08871779-20141028-C00026.TIF" alt="embedded image" img-content="chem"
view more
|
Valid
Entry 218 Entry 203 |
5 |
The hydrochloride salt of claim 4 comprising less than 0.0005% of 14-hydroxymorphinone.
|
Valid
Entry 218 Entry 203 |
6 |
A pharmaceutical formulation comprising the oxymorphone hydrochloride according to claim 4.
|
Valid
Entry 218 Entry 203 |
All Claims |
NA
|
Invalid (101)
Entry 109 |
-
Infringement
Barr Laboratories Incorporated
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
5mg, 7.5mg, 10mg, 15mg, 20mg, 30mg, 40mg oxymorphone hydrochloride extended-release tablets | US 8,871,779 B2 |
1, 2, 3, 4, 5, 6
|
Infringement
Entry 218Entry 203 |
Teva Pharmaceuticals USA, Inc.
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
5mg, 7.5mg, 10mg, 15mg, 20mg, 30mg, 40mg oxymorphone hydrochloride extended-release tablets | US 8,871,779 B2 |
1, 2, 3, 4, 5, 6
|
Infringement
Entry 218Entry 203 |